Thomas Yip

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.  With the average analyst target being $8.42, the shares are primed for further upside provided upcoming catalysts pan out in favor of the company. Benzinga is profiling Nabriva for the benefit...

Thomas Yip of FBR commented in a note on Monday that shares of Geron Corporation (NASDAQ: GERN) are undervalued. Geron's imetelstat's pilot study will be presented during the upcoming American Society of Hematology (ASH) meeting in early December. Yip stated the presentation could "attract...